Fewer compliance events seen with apixaban versus enoxaparin for extended-duration VTE prophylaxis after abdominopelvic oncologic surgery<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 27, 2022 (HealthDay News) — Apixaban is noninferior to enoxaparin for extended-duration venous thromboembolic event prophylaxis (EP) after abdominopelvic oncologic surgery, according to a study published in the October issue of The Journal of Urology<\/em>.<\/p>\n Mary E. Westerman, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a single-center prospective quality improvement study measuring patient compliance and safety with EP following abdominopelvic oncologic surgery. Baseline data were collected for six months, followed by a change from enoxaparin to apixaban treatment.<\/p>\n Overall, 161 patients were discharged with enoxaparin during the baseline period and 154 were discharged with apixaban in the intervention period. The researchers found that safety events occurred in 3.1 and 0 percent of those receiving enoxaparin and apixaban, respectively; the absolute risk difference met the prespecified noninferiority threshold. In 33.5 and 14.3 percent of enoxaparin and apixaban patients, respectively, compliance events occurred.<\/p>\n “Apixaban is noninferior to enoxaparin for EP after urologic oncology surgery. Apixaban may have a more favorable safety profile than enoxaparin, although this should be tested in a randomized controlled trial,” the authors write. “Based on these results, apixaban is now our departmental standard.”<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Bristol Myers Squibb and Pfizer, the manufacturers of apixaban.<\/p>\n